LOQUS23 THERAPEUTICS: Funding, Investors & Team (Oct 2026)
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
LOQUS23 THERAPEUTICS has raised $46.5M across 1 funding round on record, the most recent a Series A of $46.5M announced in Oct 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
LOQUS23 THERAPEUTICS Company Profile and Key Stats
Latest funding round on record: Oct 2024.
LOQUS23 THERAPEUTICS Funding Rounds
LOQUS23 THERAPEUTICS Founders and Leadership Team
Contact details for the LOQUS23 THERAPEUTICS team: 1 of 1 has an email address on file.
Start 14-day free trial →LOQUS23 THERAPEUTICS Funding Compared to Other Biotechnology Startups
LOQUS23 THERAPEUTICS' latest round of $46.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like LOQUS23 THERAPEUTICS in Biotechnology and London
Companies Similar to LOQUS23 THERAPEUTICS
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
LOQUS23 THERAPEUTICS Funding FAQs
What does LOQUS23 THERAPEUTICS do?
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
How much funding has LOQUS23 THERAPEUTICS raised?
LOQUS23 THERAPEUTICS has raised $46.5M across 1 round on record. The most recent is a Series A of $46.5M announced in Oct 2024.
When did LOQUS23 THERAPEUTICS last raise funding?
LOQUS23 THERAPEUTICS' most recent funding round on record is a Series A of $46.5M, announced in Oct 2024.
Who founded LOQUS23 THERAPEUTICS?
FundedIQ lists David Reynolds (Founder) at LOQUS23 THERAPEUTICS.
Where is LOQUS23 THERAPEUTICS headquartered?
LOQUS23 THERAPEUTICS is based in London, England, United Kingdom.
How many employees does LOQUS23 THERAPEUTICS have?
LOQUS23 THERAPEUTICS is in the 1-10 employee band.
How does LOQUS23 THERAPEUTICS' funding compare to other Biotechnology startups?
LOQUS23 THERAPEUTICS' latest round of $46.5M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's LOQUS23 THERAPEUTICS Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for LOQUS23 THERAPEUTICS is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.